experimental group:sintilimab combined with chemotherapy

3 trials

Sponsors

Nantong University, Oncology Department of PLA General Hospital, The Fifth Affiliated Hospital of Sun Yat-Sen University

Conditions

Esophageal squamous cell carcinomaNon-small cell lung cancerlung cancer

Phase 2

Study on the first-line treatment of advanced non-small cell lung cancer with sintilimab combined with chemotherapy guided by immune response related markers

RecruitingChiCTR2100044514

Oncology Department of PLA General Hospitallung cancer

Start: 2021-04-01Updated: 2021-09-20

Phase II exploratory clinical study of sintilimab combined with chemotherapy followed by immunotherapy combined with chemoradiotherapy in the first-line treatment of advanced esophageal squamous cell carcinoma

Active, not recruitingChiCTR2100052796

The Fifth Affiliated Hospital of Sun Yat-Sen UniversityEsophageal squamous cell carcinoma

Start: 2022-01-01Updated: 2022-08-16

Phase 4

Neoadjuvant and adjuvant therapy of immunization combined with chemotherapy in stage IIIA non-small cell lung cancer and explore biomakers of stage IIIA non-small cell lung cancer

Active, not recruitingChiCTR1900025813

Nantong UniversityNon-small cell lung cancer

Start: 2019-10-01Updated: 2019-09-16